Rituxan For Lupus Misses Primary, Secondary Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.
You may also be interested in...
Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?
Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need
Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?
Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need
Genentech Takes Over GlycArt Anti-CD20 Antibody Work
Enhanced antibody may work better than standard of care in blood cancers.